{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": {
    "pdf_name": "Zimmerman_et_al.__2023_",
    "source_pdf": "data/clinical_files/Zimmerman et al. (2023).pdf",
    "total_pages": 7,
    "total_blocks": 93,
    "total_characters": 22477
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 4,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "Standard Dose Flu zone and FlucelVax. HD-IIV4 was High Dose Flu- zone, RIV4 was Flublok and Adj-IV was FluAd.",
      "relevance_explanation": "This quote explicitly identifies RIV4 as Flublok and lists it alongside standard dose vaccines, confirming the vaccine brands evaluated in the study."
    },
    {
      "id": 2,
      "quote": "SD-IIV4 included Afluria, Fluarix, FluLaval, Standard Dose Flu zone and FlucelVax HD-IIV4 was High Dose Flu-",
      "relevance_explanation": "This quote specifies that Fluarix is one of the standard dose quadrivalent vaccines (SD-IIV4) used in the study, supporting the claim that Flublok was evaluated against Fluarix."
    },
    {
      "id": 3,
      "quote": "The hospital system electronic medical record EMR) and the state immunization registry were used to confirm influenza vaccination. Propensity scores with inverse probability weighting were used to adjust for potential con founders and determine rVE. Results: Of the 14 590 individuals included in the primary analysis, 3,338 were vaccinated with RIV4 and 976 were vaccinated with SD-IIV4 with the balance of 10 276 being un vaccinated Most participants",
      "relevance_explanation": "This quote shows that the study directly compared individuals vaccinated with RIV4 (Flublok) and those vaccinated with SD-IIV4 (which includes Fluarix), supporting the claim of a head-to-head evaluation."
    },
    {
      "id": 4,
      "quote": "a SD-IIV4: Afluria, Fluarix, FluLaval, SD Flu zone and FlucelVax. b For difference between those receiving RIV4 and those receiving SD-IIV4.",
      "relevance_explanation": "This quote further clarifies that Fluarix is included in the SD-IIV4 group, and that the study compared outcomes between those receiving RIV4 (Flublok) and SD-IIV4 (including Fluarix)."
    }
  ],
  "model_used": "gpt-4.1"
}